See more : MICROSALT LTD. (SALT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Guerbet SA (GBT.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guerbet SA, a leading company in the Medical – Devices industry within the Healthcare sector.
- Electronics Mart India Limited (EMIL.BO) Income Statement Analysis – Financial Results
- Shanghai Fudan Forward S&T Co., Ltd (600624.SS) Income Statement Analysis – Financial Results
- Screaming Eagle Acquisition Corp. (SCRMU) Income Statement Analysis – Financial Results
- ASM (7706.TWO) Income Statement Analysis – Financial Results
- Wacul.Inc (4173.T) Income Statement Analysis – Financial Results
Guerbet SA (GBT.PA)
About Guerbet SA
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 795.65M | 753.28M | 732.07M | 712.30M | 816.91M | 794.61M | 808.63M | 776.47M | 489.91M | 409.51M | 390.60M | 404.25M | 377.83M | 352.58M | 335.48M | 320.78M | 305.55M | 289.41M | 269.48M | 247.49M |
| Cost of Revenue | 206.76M | 564.17M | 556.40M | 554.80M | 608.09M | 213.78M | 212.66M | 209.52M | 113.28M | 98.87M | 105.89M | 115.16M | 224.70M | 98.80M | 82.11M | 71.97M | 70.26M | 66.39M | 66.43M | 50.90M |
| Gross Profit | 588.89M | 189.11M | 175.68M | 157.49M | 208.82M | 580.83M | 595.97M | 566.95M | 376.64M | 310.64M | 284.71M | 289.10M | 153.14M | 253.78M | 253.37M | 248.81M | 235.29M | 223.02M | 203.05M | 196.59M |
| Gross Profit Ratio | 74.01% | 25.11% | 24.00% | 22.11% | 25.56% | 73.10% | 73.70% | 73.02% | 76.88% | 75.86% | 72.89% | 71.51% | 40.53% | 71.98% | 75.52% | 77.56% | 77.01% | 77.06% | 75.35% | 79.44% |
| Research & Development | 81.23M | 69.98M | 65.00M | 71.42M | 72.55M | 70.40M | 67.70M | 53.38M | 37.93M | 35.30M | 36.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.28M | 11.65M | 10.71M |
| General & Administrative | 7.72M | 155.23M | 130.71M | 138.42M | 246.27M | 246.46M | 254.83M | 251.46M | 155.91M | 123.44M | 120.13M | 119.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.85M | 8.80M | 9.42M |
| Selling & Marketing | 8.00M | 8.21M | 6.28M | 8.49M | 9.21M | 8.43M | 10.56M | 179.52M | 115.77M | 104.83M | 101.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.48M | 7.09M | 6.52M |
| SG&A | 470.95M | 80.32M | 53.84M | 40.45M | 65.98M | 457.40M | 451.46M | 430.98M | 271.68M | 228.27M | 221.83M | 119.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.33M | 15.89M | 15.94M |
| Other Expenses | -1.96M | -8.36M | -20.05M | -10.65M | -17.32M | -4.74M | -27.56M | -29.09M | -18.34M | 0.00 | 0.00 | 0.00 | 301.00K | 14.00K | -135.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 550.22M | 158.66M | 138.89M | 122.52M | 155.85M | 507.51M | 523.11M | 513.34M | 314.60M | 272.70M | 255.91M | 255.58M | 130.60M | 239.79M | 227.99M | 209.00M | 198.50M | 192.37M | 168.43M | 164.76M |
| Cost & Expenses | 756.98M | 722.83M | 695.29M | 677.32M | 763.94M | 721.29M | 735.77M | 722.86M | 427.88M | 371.57M | 361.80M | 370.74M | 355.30M | 338.60M | 310.10M | 280.97M | 268.76M | 258.76M | 234.85M | 215.66M |
| Interest Income | 123.00K | 34.00K | 59.00K | 83.00K | 39.00K | 6.89M | 6.05M | 6.55M | 1.11M | 1.69M | 1.09M | 142.00K | 64.00K | 91.00K | 761.00K | 732.00K | 218.00K | 401.00K | 355.00K | 194.00K |
| Interest Expense | 10.63M | 4.57M | 5.34M | 4.85M | 7.62M | 6.90M | 6.10M | 6.87M | 1.17M | 1.45M | 1.35M | 2.36M | 4.19M | 2.65M | 3.55M | 5.53M | 3.08M | 1.70M | 2.11M | 2.03M |
| Depreciation & Amortization | 61.15M | 60.80M | 55.95M | 59.65M | 58.73M | 47.09M | 39.45M | 49.21M | 25.48M | 23.19M | 21.86M | 21.79M | 20.39M | 20.10M | 18.95M | 16.88M | 15.55M | 14.84M | 13.56M | 14.39M |
| EBITDA | 102.59M | 32.29M | 85.09M | 79.21M | 111.64M | 104.85M | 116.75M | 103.15M | 85.48M | 62.49M | 51.41M | 51.89M | 42.61M | 27.88M | 47.91M | 56.47M | 51.33M | 43.10M | 51.72M | 45.05M |
| EBITDA Ratio | 12.89% | 12.11% | 12.67% | 13.28% | 13.67% | 13.19% | 14.44% | 12.90% | 17.45% | 15.23% | 12.64% | 13.70% | 11.26% | 9.53% | 14.45% | 17.58% | 17.13% | 14.96% | 19.24% | 18.20% |
| Operating Income | 38.67M | 30.45M | 36.79M | 34.97M | 52.97M | 66.09M | 81.01M | 56.01M | 60.01M | 39.19M | 27.53M | 31.64M | 22.54M | 8.28M | 29.72M | 39.81M | 36.79M | 30.64M | 34.66M | 30.82M |
| Operating Income Ratio | 4.86% | 4.04% | 5.02% | 4.91% | 6.48% | 8.32% | 10.02% | 7.21% | 12.25% | 9.57% | 7.05% | 7.83% | 5.96% | 2.35% | 8.86% | 12.41% | 12.04% | 10.59% | 12.86% | 12.45% |
| Total Other Income/Expenses | -7.86M | -14.92M | -7.81M | -20.27M | -1.76M | 343.00K | -12.41M | -7.53M | 5.42M | -2.50M | 185.00K | -3.91M | -4.57M | -3.15M | -3.75M | -5.83M | -3.09M | -3.75M | 1.39M | -1.88M |
| Income Before Tax | 30.81M | -33.08M | 23.81M | 14.70M | 45.30M | 66.44M | 66.81M | 47.06M | 60.92M | 36.25M | 27.71M | 27.73M | 17.97M | 5.13M | 25.97M | 33.98M | 33.70M | 26.89M | 36.05M | 27.34M |
| Income Before Tax Ratio | 3.87% | -4.39% | 3.25% | 2.06% | 5.54% | 8.36% | 8.26% | 6.06% | 12.44% | 8.85% | 7.09% | 6.86% | 4.76% | 1.45% | 7.74% | 10.59% | 11.03% | 9.29% | 13.38% | 11.05% |
| Income Tax Expense | 8.64M | 8.03M | -8.83M | -3.54M | 7.97M | 19.62M | 20.59M | 18.13M | 21.69M | 10.13M | 7.22M | 7.33M | 3.54M | -751.00K | 5.48M | 9.59M | 9.94M | 7.97M | 13.04M | 10.14M |
| Net Income | 23.87M | -41.12M | 32.64M | 18.24M | 37.33M | 46.82M | 46.22M | 28.93M | 39.92M | 26.13M | 20.49M | 20.40M | 14.43M | 5.88M | 20.50M | 24.39M | 23.76M | 18.93M | 23.01M | 17.20M |
| Net Income Ratio | 3.00% | -5.46% | 4.46% | 2.56% | 4.57% | 5.89% | 5.72% | 3.73% | 8.15% | 6.38% | 5.25% | 5.05% | 3.82% | 1.67% | 6.11% | 7.60% | 7.78% | 6.54% | 8.54% | 6.95% |
| EPS | 1.90 | -3.26 | 2.59 | 1.45 | 2.97 | 3.72 | 3.69 | 2.33 | 3.21 | 2.14 | 1.68 | 1.67 | 1.18 | 0.48 | 1.69 | 2.03 | 1.98 | 1.59 | 1.95 | 1.48 |
| EPS Diluted | 1.90 | -3.26 | 2.58 | 1.44 | 2.95 | 3.70 | 3.65 | 2.29 | 3.13 | 2.07 | 1.62 | 1.61 | 1.12 | 0.48 | 1.64 | 1.96 | 1.91 | 1.53 | 1.85 | 1.44 |
| Weighted Avg Shares Out | 12.58M | 12.62M | 12.62M | 12.60M | 12.59M | 12.58M | 12.53M | 12.44M | 12.22M | 12.21M | 12.20M | 12.20M | 13.04M | 12.18M | 12.11M | 12.04M | 11.96M | 11.94M | 12.56M | 11.63M |
| Weighted Avg Shares Out (Dil) | 12.58M | 12.62M | 12.64M | 12.67M | 12.67M | 12.67M | 12.67M | 12.67M | 12.54M | 12.70M | 12.72M | 12.74M | 13.04M | 12.49M | 12.56M | 12.48M | 12.56M | 12.54M | 12.56M | 12.02M |
Source: https://incomestatements.info
Category: Stock Reports